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Summary Plasminogen activator (PA) is a serine protease existing in two forms known as tissue-type (t-PA)
and urokinase-type (u-PA). To examine whether PA is related to the postoperative clinical course of human
breast cancer, total PA activity, t-PA activity, u-PA activity, and immunoreactive t-PA were determined in
tissue extracts from 144 breast cancer specimens. The patients were initially divided into four groups according
to the postoperative clinical course: Group I (83 patients who are disease-free), Group II (20 patients whose
first metastases were found only in bone), Group III (19 patients whose first metastases were found in both
bone and lung), and Group IV (22 patients whose first metastases were found only in lung). Total PA activity
was significantly lower in Groups, II, III and IV than in Group I. Both t-PA activity and t-PA antigen levels
were also significantly lower in Groups II, III and IV than in Group I, while no significant difference was
found in u-PA activity among these groups, indicating that low activity of total PA in Groups II, III and IV
was due to a decrease in t-PA but not in u-PA. In the multivariate analyses, t-PA activity was found to be an
independent prognostic factor for relapse-free survival. When four groups of patients were further analysed in
terms of nodal status, both t-PA activity and antigen levels were markedly decreased in the node-negative
Group II compared with the node-negative Groups III and IV or with the node-positive Groups II, III and
IV. Of additional interest, u-PA activity was significantly higher in node-positive patients than in node-
negative patients with any group. The clinico-pathologic analyses of the patients in this series showed that
node involvement and lymphatic invasion were more frequently positive in Groups III and IV than in Groups
I and II. When 144 breast cancers were categorised in terms of combinations of oestrogen receptor (ER) and
progesterone receptor (PgR) status, breast cancers which were positive for both receptors were found to
contain the highest t-PA activity and antigen. This study provides provocative evidence suggesting a possible
differential significance of t-PA and u-PA expression in human breast cancer.
Many transformed or malignant tumour cells are known to
produce plasminogen activator (PA), a serine-type protease
converting plasminogen to plasmin (Unkeless et al., 1975;
Howett et al., 1978; Orenstein et al., 1983). It is widely
accepted that PA is intimately involved in the metastatic
spread of tumour cells (Dano et al., 1985; Colombi et al.,
1986; Mignatti et al., 1986; Reich et al., 1988; Ossowski et
al., 1988; Markus et al., 1988; Yu et al., 1990; Testa et al.,
1990; Hollas et al., 1991). There are two main forms of PA:
urokinase type (u-PA) and tissue-type (t-PA). While both
catalyse cleavage of the peptide bond between Arg-Val in
plasminogen, thus converting the proenzyme to plasmin, they
differ in many aspects such as their molecular weight,
immunological reactivity and amino acid sequence (Ny et al.,
1984; Riccio et al., 1985; Blasi et al., 1988).
PA expressed in breast cancer tissue has attracted attention
as (i) it is induced by oestrogen in breast cancer cells in
culture (Butler et al., 1983; Ryan et al., 1984; Yamashita et
al., 1984, 1992a; Inada et al., 1991, 1992; Mira-y-Lopez et al.,
1991), (ii) it correlates with oestrogen receptor (ER) and/or
progesterone receptor (PgR) content in human breast cancer
(Sutherland, 1980; Thorsen, 1982; Yamashita et al., 1986;
Pacheco et al., 1988), and (iii) there are analogous effects of
hormones, including oestrogen, on breast cancer growth and
PA expression (Mak et al., 1976; Mira-y-Lopez et al., 1983,
1985; Butler et al., 1986). In a multivariate analysis we
recently showed a significant association between low levels
of total PA activity and poor prognosis of breast cancer
patients and suggested the value of total PA assays as a
prognostic indicator for disease-free and overall survival
(Yamashita et al., 1993). This was unexpected in the light of
previous publications that showed a poorer disease-free and
overall survival for breast cancer patients whose tumours
contain an elevated u-PA activity and/or antigen (Duffy et
al., 1990; Janicke et al., 1990). In this study, we therefore
evaluated the t-PA and u-PA components of total activity, in
the hope that this might resolve the apparent discrepancy
between our report and those of others.
We have previously measured the concentration of t-PA in
tissue extracts from 27 human breast cancers and presented
preliminary evidence that patients with only-bone metastases
had significantly less t-PA antigen level in their primary
breast tumours than those with metastases to other organs
(Yamashita et al., 1992b). We have now extended this study
and determined not only t-PA antigen level but also t-PA
and u-PA activities in primary breast cancer tissues. These
enzyme activities are compared with the postoperative
clinical course of the patients. We report here that (i) a
greater proportion of total PA activity is composed of t-PA
in primary breast cancer tissues, and a decrease in t-PA, but
not u-PA, is responsible for the low activity of total PA in
patients with poor prognosis, (ii) t-PA activity and antigen
levels are extremely low in patients with only-bone metas-
tases from node-negative breast cancers, (iii) it is u-PA rather
than t-PA that is involved in lymphatic dissemination which
might subsequently develop into lung metastases. A possible
differential significance of t-PA and u-PA expression in
human breast cancer is discussed.
Patients and methods
Patients
This retrospective study was based on the records of 144
breast cancer patients who underwent curative mastectomy in
the Department of Surgery II, Kumamoto University Hos-
pital, during the 6 year period from 1981 to 1986. The
median follow-up period for patients was 7.7 years (range,
6.6- 11.2 years). These patients were divided into four groups
according to the postoperative clinical course: Group I (83
patients who remained free of distant metastases), Group II
(20 patients whose first metastases were found only in bone
and remained confined in bone within 12 months), Group III
(19 patients whose first metastases were found in both bone
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and lung simultaneously, or those whose first metastases were
found in bone or lung and subsequently detected in the other
site within 12 months), and Group IV (22 patients whose first
metastases were found only in lung and remained confined in
lung within 12 months. Group III included 3 patients who
had also liver metastases. The median follow-up for patients
in each group was: Group I, 9.1 years; Group II, 7.9 years;
Group III, 7.2 years; and Group IV, 6.6 years.
The routine follow-up of these patients after surgery con-
sisted of clinical evaluation every 3 months in the first year
and every 6 months thereafter. Disease recurrence was
documented by physical examination and radiological and
laboratory tests. At the time that bone metastases were first
documented, a bone scanning and bone roentgenograph were
used for the detection of the metastatic bone lesions. Also, at
the time that lung metastases were first documented, chest
roentgenograph and computed tomographic (CT) scanning of
the lung were used. At the time that the first recurrence was
discovered, a bone scanning, radiography or CT scanning of
the lung, CT or ultrasonic scanning of the liver, CT scanning
of the brain, and if necessary lymph node or skin biopsy
were performed to exclude metastases in other sites.
The clinico-pathologic parameters reviewed in this study
were age, menstrual status, tumour size, node involvement,
histologic type, histologic grade, lymphatic invasion, vascular
invasion, ER, PgR, type of surgery and type of adjuvant
therapy. Tumour size was recorded at the greatest diameter
of the tumour. The extent of lymph node metastases was
categorised into one of three groups: 0, 1 to 3 and 4+. When
histopathological typing was performed in 144 breast cancers
according to the WHO classification (1981), all tumours in
our series were classified into the same category, i.e., invasive
ductal carcinoma. Therefore, each tumour was further
analysed according to the classification of the Japanese
Breast Cancer Society (1988) and was graded in parallel
according to the criteria described by Bloom and Richardson
(1957). ER and PgR were determined by the dextran-coated
charcoal method as described previously (McGuire et al.,
1977). Tumour specimens were considered hormone receptor-
positive if they contained at least 10 fmol specific binding
sites mg-' protein.
Assayfor PA
The analyses in this study focused on whether or not the PA
levels in the primary tumours differed among four groups.
Samples for enzyme assay were prepared using 50 mM Tris-
HCl buffer (pH 7.4) containing 0.25% Triton X-100, as des-
cribed previously (Yamashita et al., 1984). Total PA activity
was determined as described previously (Yamashita et al.,
1984) in a coupled assay using S-2251 (H-D-Val-Leu-Lys-
pNA, Kabi, Stockholm) as a substrate for plasmin. t-PA and
u-PA activities were assayed according to the method of
O'Grady et al. (1985) except that monoclonal antibodies to
t-PA and u-PA (Cosmo Bio., Tokyo) were employed. Briefly,
to measure the t-PA and u-PA activities, total PA activity
was determined in the presence and absence of quenching
antibodies against t-PA and u-PA. The activity in the
presence of anti-t-PA antibody and anti-u-PA antibody was
regarded as the u-PA and t-PA activity, respectively. In most
cases, the proportion of activity quenched by anti-t-PA and
anti-u-PA antibodies always added up to approximately
100%, indicating that t-PA and u-PA were the only forms of
total PA present in the tissue extracts. The t-PA antigen level
was determined with an enzyme-linked immunosorbent assay
(ELISA) described by Bergsdorf et al. (1983).
Statistical analyses
Non-parametric statistics were used throughout. For compar-
ing differences between two different groups, the Mann-
Whitney U-test was used. For database management and
descriptive statistics, the SAS program (1985) was used. Life-
table analysis and Cox analysis (1972) were performed using
the BMDP statistical package program for the computer
(IBM 4381, IBM, New York).
Results
Correlation between PA levels and metastasis status
Table I shows the correlation between PA levels and post-
operative clinical course of 144 patients. When total PA
Table I Comparison of PA levels among four groups of patients
Group
I II III IV
Total patients (83) (20) (19) (22)
Total PA activity 184 ± 95a 39 ± 26 50 ± 27 54 ± 27
u-PA activity 28±17 31±11 24±10 31±16
t-PA activity 166 + 82a 12 ± 5b 30 ± 19 30 ± 14
t-PA antigen 6.0 ± 3.5a 1.2± 0.7b 2.7 ± 1.3 3.2 ± 1.8
Group
I II III IV
Node-negative patients (38) (14) (7) (7)
Total PA activity 191 ± 103a 33 ± 24 58 ± 34 51 ± 25
u-PA activity 22 ± 13e 27 ± llf 18± 9+ 20± llf
t-PA activity 184 ± 89a 8 ± 3b,g 41 ± 24 37 ± 16
t-PA antigen 6.1 ± 3.4c 0.6± 0.4b 3.1 ± 2.0 2.9± 1.5
Group
I II III IV
Node-positive patients (45) (6) (12) (15)
Total PA activity 178 ± 89a 54 ± 32 46 ± 19 55 ± 27
u-PA activity 33 ± 21 39 ± 10 28 ± 10 36 ± 17
t-PA activity 151 ±77a 21 ± 11 24± 15 27± 12
t-PA antigen 5.9 ± 3.6d 2.6 ± 1.4 2.5 ± 0.9 3.3 ± 1.9
All values represent the mean ± s.d.; PA activity (unit mg- protein), PA
antigen (ng mg- I protein). Values in parentheses are the number of patients.
aSignificant vs Groups II, III and IV; P <0.01. bSignificant vs Groups I, III
and IV; P <0.01. cSignificant vs Group II; P <0.01, vs Group III;
P<0.05, vs Group IV; P<0.05. dSignificant vs Group II; P<0.05, vs
Group III; P <0.01, vs Group IV; P <0.01. 'Significant vs u-PA activity of
node-positive Group I; P <0.01. 'Significant vs u-PA activity of respective
node-positive groups; P <0.05. gSignificant vs t-PA activity of
node-positive Group II; P <0.01. No significant difference of PA levels
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activity was compared among the four groups, more than
3-fold higher activity was found in recurrence-free patients
(Group I) than in patients with recurrence (Groups II, III
and IV). Although a greater proportion of total PA activity
consisted of t-PA (approximately 86% of total activity) in
Group I, t-PA activity was markedly decreased in Groups II,
III and IV. In contrast to t-PA, no significant difference was
found in u-PA activity among these groups. t-PA antigen
levels were also significantly lower in Groups II, III and IV
than in Group I, indicating that specific decrease in t-PA is
responsible for the low activity of total PA in patients with
recurrence. When further analyses were performed in terms
of nodal status, a similar result was obtained. As shown in
Table I, total PA activity, t-PA activity and t-PA antigen
levels were significantly lower in Groups II, III and IV than
in Group I regardless of nodal status, while u-PA activity did
not differ significantly among these groups. In the Cox's
multivariate analyses including t-PA activity and other recog-
nised prognostic factors of age, menstrual status, tumour
size, lymph node involvement, histologic type, histologic
grade, vessel involvement, and hormone receptor status, t-PA
activity was found to be an independent prognostic factor for
disease-free survival of about the same import as lymph node
involvement (relative risk; 2.4 and 2.2, respectively). In this
analyses, the optimal cut-off point of t-PA activity to give a
statistically significant separation for risk of relapse was
determined as 75 unitmg-' protein.
The second observation was that t-PA activity and antigen
levels were extremely low especially in node-negative Group
II patients (Table I). In node-negative patients, t-PA activity
and antigen levels in Group II were approximately 20% of
those in Groups III or IV, although no significant difference
was found in t-PA levels between Group II and Groups III
or IV in node-positive patients. Furthermore, when u-PA
activity was compared between node-negative and node-
positive patients, the enzyme activity was significantly higher
in the latter than in the former with any group.
Comparison ofclinico-pathologicalfactors among 4 groups of
patients
Table II summarises the clinical characteristics of 144
patients studied. No significant difference was found among
four groups with respect to age, menstrual status, tumour
size, histologic type, histologic grade, vascular invasion, ER,
PgR, type of surgery and type of adjuvant therapy. However,
two node-related parameters were significantly different
among four groups. Lymph node metastases were found
significantly more often in Group IV than in Groups I and II
(P<0.01 and P<0.05, respectively), and histological lym-
phatic invasion was present more frequently in Groups III
and IV than in Group I (P<0.05 and P<0.01, respectively)
and Group II (not significant and P<0.05, respectively).
Correlation between PA levels and hormone receptor status
t-PA is an oestrogen-inducible enzyme and thus its presence
may imply an intact ER system. We speculated therefore that
the difference of t-PA levels among four groups (Table I)
probably reflects the functional state of hormone receptors.
To test this, PA levels were compared in terms of the pattern
of hormone receptor combinations, although Table II
showed no significant correlation between the groups and ER
or PgR. As shown in Table III, tumours which were
ER(+)(PgR(+) showed significantly higher t-PA activity and
antigen levels than tumours which belong to other combina-
tions of ER and PgR status.
Correlation between t-PA activity and t-PA antigen level
To compare the proportion of t-PA activity to antigen level
among four groups, t-PA antigen levels were converted to
activity by specific activity of t-PA. The value of specific
activity was estimated to be 48.8 unit ng-' when a serial
amount of recombinant t-PA (not including PA inhibitors,
Cosmo Bio., Tokyo) was used as control. As sh6wn in Table
IV, t-PA activity/t-PA antigen (converted activity) ratio was
significantly lower in patients with recurrence (Groups II, III
and IV) than in recurrence-free patients (Group I) (P<0.001
both in node-negative groups and in node-positive
groups).
Discussion
Previous studies have demonstrated a poorer disease-free and
overall survival for breast cancer patients whose tumours
contain an elevated u-PA activity and/or antigen (Duffy et
al., 1990; Janicke et al., 1990). However, in the retrospective
study of early breast cancer patients, there was a statistically
Table II Clinico-pathological status in 144 breast cancer patients
studied
Group
I II III IV
Parameters n =83 n =20 n = 19 n =22
Age
< 50 year
> 50 year
Menstrualstatus
Premenopause
Postmenopause
Tumoursize
<2cm
2- cm
>5cm
Node involvementa
0
1-3
>4
Histologic type
Papillotubular
Solid-tubular
Scirrhous
Others
Histologicalgrade
Grade I
Grade II
Grade III
Lymphatic invasionb
Negative
Positive
Vascular invasion
Negative
Positive
Oestrogen receptor
Negative
Positive
Unknown
Progesterone receptor
Negative
Positive
Unknown
Type ofsurgery
Radical
Modified radical
Simple
Typeofadjuvant therapy
Chemotherapy
Endocrine therapy
Chemo-endocrine therapy
No therapy
35(42) 11(55) 8(42) 8(36)
48(58) 9(45) 11(58) 14(64)
42(51) 13(65) 9(47) 11(50)
41(49) 7(35) 10(53) 11(50)
19(23)
54(65)
10(12)
27(33)
31(37)
25(30)
18 (22)
38(46)
24(29)
3(4)
29(35)
29(35)
25(30)
2(10)
12(60)
6(30)
7(35)
7(35)
6 (30)
2 (10)
12(60)
6(30)
0(0)
6 (30)
8 (40)
6(30)
2(11)
13(68)
4(21)
2(11)
8 (42)
9(47)
1 (5)
10(53)
8(42)
0(0)
4 (21)
7(37)
8 (42)
4 (18)
14(64)
4(18)
2 (9)
6 (27)
14(64)
2 (9)
1 (50)
9(41)
0(0)
5(23)
7(32)
10(45)
51(61) 11(55) 6 (32) 4 (18)
32(39) 9(45) 13(68) 18(82)
46(55) 7(35) 9(47) 12(55)
37(45) 13(65) 10(53) 10(45)
31 (37)
46(55)
6(7)
45(54)
31 (37)
7(8)
49(59)
32(39)
2(2)
10(12)
29(35)
38(46)
6(7)
8(40)
10(50)
2(10)
12(60)
6(30)
2(10)
13 (65)
7(35)
0(0)
3 (15)
8(40)
9(45)
0 (0)
8(42)
10(53)
1 (5)
12(63)
6(32)
1(5)
10(53)
9(47)
0 (0)
11 (50)
9(41)
2 (9)
12(55)
8 (36)
2 (9)
13 (59)
9 (41)
0 (0)
4 (21) 4(18)
8 (42) 8 (36)
7 (37) 10(45)
0(0) 0(0)
Values in parentheses are the percentage ofpatients in each group.
aSignificant: between Group I and Group IV (P<0.01). Between
Group IIand Group IV (P <0.05). bSignificant: between Group I
and Group III (P<0.05). Between Group I and Group IV
(P<0.01). Between Group II and Group IV (P <0.05). No
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Table III Relationship between PA levels and hormone receptor status in 144 breast cancers
ER unknown
ER (+) ER (+) ER (-) ER (-) ER (+) PgR
PgR (+) PgR (-) PgR (+) PgR (-) PgR unknown unknown
(43) (31) (8) (50) (1) (11)
Total PA activity 202 ± lola 94 ± 57 116 ± 35 88 ± 59 129 103 44
u-PA activity 25± 15 32±21 29± 13 30± 14 41 22 10
t-PA activity 184± 83b 68± 35 90±51 69± 32 90 88±49
t-PA antigen 6.3 ± 3.2c 3.8 ± 1.9 4.1 ± 1.7 3.4± 2.0 3.8 4.4±2.1
One hundred and forty-four patients were categorised in terms of the hormone receptor status (four possible
combinations). Hormone receptor positivity was defined as IO fmol mg-' protein. All values represent the
mean ± s.d.; PA activity (unitmg-' protein), PA antigen (ngmg-' protein). Values in parentheses are the
number of patients. aSignificant vs ER(+)PgR(-), ER(-)PgR(-); P <0.01, vs ER(-)PgR(+); P <0.05, vs
unknown and unknown; P <0.01. bSignificant difference vs ER(+)PgR(-), ER(-)PgR(-), known and
unknown; P <0.01, vs ER(-)PgR(+); P <0.01.cSignificant vs ER(+)PgR(-), ER(-)PgR(-); P <0.01. No
significant difference of PA levels between any other combinations of groups.
Table IV Correlation between t-PA activity and antigen level in human
breast cancer
Group
I II III IV
Node-negativepatients (38) (14) (7) (7)
t-PA activity 184 ± 89 8 ± 3 41 ± 24 37 ± 16
t-PAantigen 298± 166 29 20 151 ±98 142 73
(converted activity)
Activity/antigen ratio 0.65± 0.21a 0.24± 0.11 0.27± 0.09 0.26± 0.12
Group
I II III IV
Node-positivepatients (45) (6) (12) (15)
t-PAactivity 151 77 21 11 24 15 27 12
t-PAantigen 288 176 127 68 122 44 161 93
(converted activity)
Activity/antigen ratio 0.55± 0.23a 0.17± 0.10 0.22± 0.12 0.16± 0.08
t-PA antigen levels were converted to activity by specific activity of t-PA
(48.8 units ng -). All values represent the mean ± s.d.: t-PA activity and
t-PA antigen (unit mg-' protein), activity/antigen ratio (%). Values in
parentheses are the number of patients. aSignificant difference vs Groups II,
III and IV; P<0.01.
significant adverse association between low levels of total PA
activity and patient survival (Yamashita et al., 1993). The
present study has resolved the discrepancy between these
results. Our assay for total PA activity proved to be biased
towards t-PA, that is, a greater proportion of total PA
activity consisted of t-PA in breast cancer tissues, and
therefore, a specific decrease in t-PA was responsible for the
low activity of total PA seen in unfavourable groups of
patients. Although the reason why a high t-PA activity in
primary breast cancer tissues indicates a good prognosis
remains unclear, this result is compatible with that reported
by Duffy et al. (1988). This may be related to the fact that
t-PA is an oestrogen-inducible enzyme and thus reflects an
intact ER system, since the presence of oestrogen dependency
in breast cancer is generally thought to be associated with a
good prognosis (Foekens et al., 1989). Indeed, analyses of
144 patients in this series showed tumours which were
positive for both ER and PgR contained significantly higher
t-PA activity and antigen. In the multivariate analyses, t-PA
activity was found to be a significant prognostic indicator.
Patients with breast cancer containing high t-PA activity are
considered to have a favourable prognosis, who might be
candidates for being spared the necessity of adjuvant
therapy.
Although bone metastases, without evidence of tumour
deposits in other organs such as lung and liver, occur com-
monly in breast cancer, the mechanisms underlying the
occurrence of these metastases are poorly understood. Metas-
tases occur more commonly in the axial bones than in the
appendicular bones, and often remain localised in the bone
for a long time without any other evidence of metastases.
One possible mechanism of this state ofonly-bone metastases
is Batson's concept. Batson (1940) and Henriques et al.
(1962) suggested that breast cancer may spread to the verteb-
ral column and the axial bones through retrograde venous
seeding without passing through the pulmonary circulation.
Recently, Yamashita et al. (1991) also reported that patients
who had bone metastases exclusively cranial to the lumbosac-
ral junction had a significantly higher visceral metastases-free
rate, and suggested an important role of vertebral venous
plexus in only-bone metastases.
Tumour cell emboli were the most important event closely
associated with the lodgement of the circulating tumour cells,
and only tumour cell emboli with dense aggregation of
platelets and formation of fibrin could develop into metas-
tatic foci (Hilgard, 1973; Warren, 1973). Furthermore, it has
been stressed that the most important factors influencing the
ability to form fibrin with clumping of tumour cells would be
fibrinolytic activity of tumour cells themselves rather than
that of blood itself (Warren, 1973; Kinjo, 1978). While both
t-PA and u-PA cleave the same single peptide bond in plas-
minogen to convert it into plasmin, t-PA is distinguished by
its high affinity for fibrin. The binding of t-PA to fibrin
causes a marked stimulation in its fibrinolytic activity
(Holyaerts et al., 1982). The present study demonstrated that
t-PA activity and antigen levels in primary tumours are
extremely low in patients with only-bone metastases from
node-negative breast cancers, although the small numbers of
patients in the various groups precluded a multivariate
analysis. Thus, it is reasonable to expect that t-PA inhibits
bone metastases formation by virtue of its fibrinolytic activity
which may prevent the lodgement of cancer cells drifting in
the vertebral venous plexus. Our interest in this hypothesis
stems mainly from the possibility that t-PA may provide an
effective strategy for prevention and treatment of bone
metastases from human breast cancer.528 J. YAMASHITA etal.
t-PA activity and antigen levels must be distinguished
because of the inactivation of PA by PA inhibitors present in
breast cancer tissues (Reilly et al., 1990). There are at least
two kinds of specific inhibitor which act on PA: type-I and
type-2 PA inhibitors (PAI-I and PAI-2, respectively). PAI-i
forms 1:1 complex with both u-PA and t-PA, and is thought
to be a natural inhibitor of t-PA in plasma, although PAI-2
was shown to inhibit u-PA about ten times more strongly
than t-PA (Astedt et al., 1987). Although PA inhibitors in
tissue extracts were not determined in this study, the t-PA
activity/t-PA antigen ratio was significantly lower in patients
with recurrence compared with recurrence-free patients, sug-
gesting that PA inhibitors affected t-PA activity in tissue
extracts to a greater extent in the former than in the latter.
This relative increase in PA inhibition in unfavourable
groups may be related to the fact that a significant positive
correlation was found between PAI-I levels and the metas-
tatic potential of breast cancer cells (Reilly et al., 1990;
Sumiyoshi et al., 1991, 1992). However, further studies are
necessary in this respect.
With respect to u-PA, this enzyme is supposed to be a key
enzyme in the breakdown of extracellular matrix proteins
during tissue destruction in a variety of normal and
pathological conditions, including the invasive growth and
metastasis of cancer cells (Layer et al., 1987; Hearing et al.,
1988; Yu et al., 1990; Ossowski et al., 1992). The u-PA-
plasmin-collagenase activation cascade plays various impor-
tant roles in facilitating cancer cell invasion (Paranjpe et al.,
1980; Mignatti et al., 1986). The present study also demon-
strated that u-PA activity in the primary tumour was
significantly higher in node-positive patients than in node-
negative patients. Furthermore, clinico-pathological analyses
showed a preponderance of lymphatic extension in the group
with lung-only or lung and bone metastases. These results
suggested that u-PA is closely linked to lymphatic dissemina-
tion which subsequently developed into lung metastases.
In conclusion, this is the first report determining u-PA and
t-PA levels in breast cancer tissues in terms of different
patterns of metastatic spread. The results demonstrated here
have provided provocative evidence suggesting a differential
biological significance of t-PA and u-PA coexpressed in
human breast cancer.
We are grateful to Mr K. Akasaka of IBM Co. Ltd. (Tokyo) for
assistance with statistical analyses.
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